Skip to content

D&A at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$75.6M+8.6%
BioLife Solutions logo
BioLife SolutionsBLFS
$85K+28.8%
Opko Health logo
Opko HealthOPK
$18.97M-4.5%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$67.15M-44.2%
Revvity logo
RevvityRVTY

Segments

By segment

See full
Multiomics$3.96M+8.4%

Other financials

Income statement

See full
Revenue$144.8M+1.0%
Gross profit$62.0M-1.2%
Operating income-$165.8M-811%
Net income-$160.8M-237%
EPS (diluted)-$3.49-236%

Balance sheet

See full
Cash & equivalents$125.2M
Total debt$55.7M
Total equity$1.6B-8.3%
Total assets$1.9B

Cash flow

See full
Operating cash flow$13.5M-6.2%
CapEx$7.4M-0.1%
Free cash flow$6.1M-12.7%

Valuation

See full
Market cap$1.1B-16.3%
Enterprise value$1.03B
P/S1.8×-0.2×

Profitability

See full
Gross margin40%-1.0pp
Operating margin-31.6%-59.7pp
Net margin-29.1%-80.7pp
FCF margin8.6%

Returns & leverage

See full
Return on equity-10.7%-22.4pp
Debt / equity
Current ratio2.8×

Where this comes from

Reported directly by Azenta in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Azenta’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Azenta's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Azenta's D&A?
Azenta (AZTA) reported D&A of $14M in Q1 2026.
How has Azenta's D&A changed year-over-year?
Azenta's D&A increased by 0.4% year-over-year, from $13.95M to $14M.
What is the long-term trend for Azenta's D&A?
Over 4 years (2021 to 2025), Azenta's D&A has grown at a -1.6% compound annual growth rate (CAGR), from $65.33M to $61.21M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.